CDSCO Panel Recommends Phase III Trial of Tetanus Vaccine by Indian Immunologicals in Pregnant Women
New Delhi: The Subject Expert Committee (SEC) for Vaccines under the Central Drugs Standard Control Organisation (CDSCO) has recommended the conduct of a Phase III clinical trial for the Tetanus Vaccine (Adsorbed, I.P.) developed by Indian Immunologicals Limited, Hyderabad.
The recommendation came during the SEC meeting held on May 22, 2025, through hybrid mode, where the panel reviewed and re-deliberated the firm’s proposal [File No. BIO/CT/23/000129].
Indian Immunologicals presented crucial data in response to earlier observations made by the SEC during its meeting on February 5, 2024. The submission included:
Developmental and Reproductive Toxicity (DART) study reports conducted in rats and rabbits.
Post-marketing safety data of the marketed vaccine.
Published literature on the vaccine's safety and efficacy.
After detailed examination of the submitted documentation and data, the expert panel gave the go-ahead to conduct the Phase III clinical trial specifically in healthy pregnant women, as per the protocol submitted by the company.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.